come on Tom 80 cents is long gone mate!
mind you.... one argument is if ARX is worth 250 million market cap on 6 products and 36 million revenue (and have been around longer) whats PNV worth at 44 million revenue (20% more)
it would suggest either one stock is too cheap pr another too expensive or there is other considerations at play
i think ARX looks seriously under valued and should be with 80% yoy growth and in healthcare space have at least a 10x revenue valuation of 360 million
Novosorb is able to achieve 44 million off less people newer patented product has more us GPOs signed then ARX .
PNV - Banter and General Comments, page-7895
-
- There are more pages in this discussion • 4,114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35541 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 2681 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |